Mesoblast Ltd
mesoblast.comWhat Do They Do?
Sells Ryoncil, a cell-based treatment for children with steroid-refractory acute graft-versus-host disease, and develops cell therapies for patients with cardiovascular, immune and spine conditions.
20-F for FY2026, filed Aug 27, 2026In December 2024, the FDA approved Mesoblast’s Ryoncil® for the treatment of pediatric SR-aGvHD in children 2 months and older. The Group…View ↗
Mesoblast's most significant contribution to sustainability lies in its core mission: expanding access to innovative treatments for…View ↗
We recognize that as a biotechnology company developing innovative, cell-based medicines, our stakeholders – including patients, HCPs…View ↗
Who Are Their Customers?
Product sales flow through the U.S. distribution channel; pharmaceutical partners receive regional rights and handle development or commercialization in their markets.
20-F for FY2026, filed Aug 27, 2026The Group has credit risk exposure to customers in the U.S. distribution channel. As at June 30, 2026 and 2025, 98.0% and 89.3% of the…View ↗
In September 2019, the Group entered into a strategic partnership with Grünenthal for the development and commercialization in Europe and…View ↗
In July 2018, the Group entered into a strategic alliance with Tasly Pharmaceutical Group (“Tasly”) for the development, manufacture and…View ↗
Do Revenues Turn Into Profits?
No. It lost $57.5M in .
20-F for FY2026, filed Aug 27, 2026
20-F for FY2026, filed Aug 27, 2026
−$57.5MView ↗
How Are They Changing?
Commercial product
The older report described remestemcel-L as awaiting U.S. approval for pediatric steroid-refractory acute graft-versus-host disease; the latest report says Ryoncil received approval and Mesoblast began commercializing it for that use.
20-F for FY2023, filed Aug 31, 2023 20-F for FY2026, filed Aug 27, 2026United States Food & Drug Administration (“FDA”) provided a complete response to the Biologics License Application (“BLA”) resubmission for…View ↗
Loading...
